ERBB2 and neoplasm: Our ability to detect anti-HER2 antibody at the tumor site but not in the blood of NSC-treated mice suggests that this approach could have robust localized anti-tumor effect, while minimizing the systemic toxicity associated with traditional trastuzumab therapy.